Biomarker changes associated with fornix deep brain stimulation in Alzheimer's disease.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Germann Jürgen, Amaral Robert S C, Tomaszczyk Jennifer, Yamamoto Kazuaki, Elias Gavin J B, Gouveia Flavia Venetucci, Vasilevskaya Anna, Taghdiri Foad, Devenyi Gabriel A, Sankar Tejas, Leoutsakos Jeannie-Marie, Munro Cynthia A, Rosenberg Paul B, Lyketsos Constantine G, Oh Esther S, Anderson William S, Mari Zoltan, Fosdick Lisa, Drake Kristen E, Targum Steven D, Pendergrass Jo Cara, Burke Anna, Salloway Stephen, Asaad Wael F, Ponce Francisco A, Sabbagh Marwan, Wolk David A, Baltuch Gordon, Okun Michael S, Foote Kelly D, Giacobbe Peter, McAndrews Mary Pat, Tang-Wai David F, Smith Gwenn S, Tartaglia M Carmela, Chakravarty M Mallar, Lozano Andres M, Alzheimer's Disease Neuroimaging Initiative
Аннотация
METHODS: Repeated magnetic resonance imaging and positron emission tomography (PET) images acquired over the course of 12 months were used to assess changes in hippocampal volume in 36 ADvance trial patients compared to 40 matched untreated AD patients from the Alzheimer's Disease Neuroimaging Initiative, and in 10 separate patients with repeated flutemetamol PET and cerebrospinal fluid (CSF) markers.
RESULTS: We observed a reduction of hippocampal atrophy and amyloid beta (Aβ) PET binding, and an increase in the CSF Aβ/total-tau ratio in DBS patients.
DISCUSSION: These findings highlight the potential of fornix deep brain stimulation to modify AD biomarkers and possibly progression in some patients.
HIGHLIGHTS: Fornix deep brain stimulation (fx-DBS) is being investigated to treat Alzheimer's disease (AD). Results show that fx-DBS modifies imaging and cerebrospinal fluid (CSF) markers. It reduces hippocampal atrophy and increases the amyloid beta/total-tau CSF ratio. These findings highlight the potential of fx-DBS to modify AD.